The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index; 46 of the 120 sources its claims cite were checked for support.
An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact
Open accessAbstract
Paracetamol remains the recommended first-line option for mild-to-moderate acute pain in general population and particularly in vulnerable populations. Despite its wide use, debate exists regarding the analgesic mechanism of action (MoA) of paracetamol. A growing body of evidence challenged the notion that paracetamol exerts its analgesic effect through cyclooxygenase (COX)-dependent inhibitory effect. It is now more evident that paracetamol analgesia has multiple pathways and is mediated by the formation of the bioactive AM404 metabolite in the central nervous system (CNS). AM404 is a potent activator of TRPV 1 , a major contributor to neuronal response to pain in the brain and dorsal horn. In the periaqueductal grey, the bioactive metabolite AM404 activated the TRPV 1 channel‐mGlu5 receptor‐PLC‐DAGL‐CB1 receptor signaling cascade. The present article provides a comprehensive literature review of the centrally located, COX-independent, analgesic MoA of paracetamol and relates how the current experimental evidence can be translated into clinical practice. The evidence discussed in this review established paracetamol as a central, COX-independent, antinociceptive medication that has a distinct MoA from non-steroidal anti-inflammatory drugs (NSAIDs) and a more tolerable safety profile. With the establishment of the central MoA of paracetamol, we believe that paracetamol remains the preferred first-line option for mild-to-moderate acute pain for healthy adults, children, and patients with health concerns. However, safety concerns remain with the high dose of paracetamol due to the NAPQI-mediated liver necrosis. Centrally acting paracetamol/ p -aminophenol derivatives could potentiate the analgesic effect of paracetamol without increasing the risk of hepatoxicity. Moreover, the specific central MoA of paracetamol allows its combination with other analgesics, including NSAIDs, with a different MoA. Future experiments to better explain the central actions of paracetamol could pave the way for discovering new central analgesics with a better benefit-to-risk ratio. Keywords: paracetamol, acetaminophen, AM404, analgesia, molecular targets
Overview
CoChat Summary
TL;DR
This review argues that paracetamol analgesia is centrally mediated by its AM404 metabolite and is largely COX-independent, involving TRPV1, CB1, Cav3.2, and serotonergic pathways. It concludes that paracetamol remains a first-line option for mild-to-moderate acute pain and that centrally acting paracetamol analogs may improve analgesia without NAPQI-mediated hepatotoxicity.
Key findings
- Paracetamol is converted centrally to the bioactive metabolite AM404: after hepatic deacetylation to p-aminophenol, FAAH converts it to AM404 in the brain. The first human evidence detected AM404 in cerebrospinal fluid in 17 of 26 patients who received 1 g paracetamol.
- AM404 activates TRPV1 and, in the periaqueductal grey, the TRPV1 channel–mGlu5 receptor–PLC–DAGL–CB1 receptor signaling cascade; Cav3.2 T-type calcium channels act mainly supraspinally and downstream of TRPV1, and serotonergic pathways also contribute.
- The analgesic mechanism is described as COX-independent: paracetamol’s antinociceptive profile differs from ibuprofen, COX-3 is unlikely to be clinically relevant in humans, and COX inhibition is more closely related to hypothermic/antipyretic effects.
- Clinically, paracetamol is presented as first-line for mild-to-moderate acute pain in healthy adults, children, and patients with health concerns; the maximum recommended dose is 1 g every 4–6 hours up to 4 g/day, while hepatotoxicity from NAPQI remains a major safety issue.
Methods
- Narrative literature review: Medline via PubMed was searched from inception to May 2022 using the keywords (paracetamol[MeSH Terms]) OR (acetaminophen[MeSH Terms])) AND (AM404), complemented by manual screening of relevant references.
- Evidence was synthesized narratively from experimental animal studies, human cerebrospinal fluid and genetic studies, clinical trials, and a table of selected randomized trials of paracetamol plus opioids for acute postoperative pain.
- No systematic review, meta-analysis, or formal quantitative synthesis was reported.
Limitations
- The paper states that evidence for the morphine-sparing effect of paracetamol/opioid combinations is limited and further studies are needed; the exact nature of the spinal tropisetron-sensitive receptor involved remains to be elucidated; and how CB1 receptors are involved requires further study.
- The paper states that safety issues remain controversial or inconclusive, including hepatotoxicity, and that some combination safety signals—such as hemoglobin decreases with longer-term paracetamol/ibuprofen and upper GI events with NSAID plus acetaminophen—warrant further research.
- Evident from the text: as a narrative review, it does not report a systematic search beyond PubMed and the AM404 keyword strategy, nor a formal quality/risk-of-bias assessment or quantitative synthesis, so clinical recommendations rest on selected evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
34 Valid · 3 Not valid · 35 Not checked · 34 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In 2014, Kerckhove et al demonstrated that Cav3.2 knockout mice had impaired response to the analgesic effect of a systemic administration of paracetamol or intracerebroventricular injection of AM404.55”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > AM404-Modulated Molecular Targets > Downstream Targets of TRPV1
What the sources say
- Partly supportedcites [55] Barbara, 2009, J Neurosci sourceExperimental — accuracy not yet measured
The section “NAGly and NAGABA-OH produce thermal analgesia via Cav3.2 inhibition” reports that these compounds produced analgesia in wild-type mice but not Cav3.2 knockout mice. The Behavioral studies methods describe hindpaw injections, not systemic paracetamol or intracerebroventricular AM404; our copy does not report responses to either drug by those routes. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Importantly, it has been shown that 1) centrally injected AM404 induced analgesia37,44,45”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > AM404: The Active Metabolite of Paracetamol
What the sources say
- Supportedcites [37] Mallet, 2010, PLoS One source
The Results report that intracerebroventricular injection of AM404 reduced pain-related behavior in the mouse formalin test. The authors conclude in the Results that AM404 produces antinociception when injected into the brain, supporting the claim that centrally injected AM404 induces analgesia. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [44] Rastogi, 2008, J Clin Oncol source
- Supportedcites [45] Kerckhove, 2014, Pain source
The Results (Manuscript-KERCKHOVE, p. 9) report that intracerebroventricular injection of AM404 induced analgesia in Cav3.2 +/+ mice in the formalin and von Frey tests. The same passage notes that this effect was not observed in Cav3.2 -/- mice. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, paracetamol remains the mainstay analgesic option in patients with chronic kidney disease.92”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Potential Clinical Consequences of the Centrally Located Analgesic Action of Paracetamol > Paracetamol, a COX-Independent, Centrally Acted as the First Choice for a Wide Range of Special Populations
What the sources say
- Supportedcites [92] Davison, 2020, Can J Kidney Heal Dis source
The Discussion states that acetaminophen (paracetamol) is the mainstay of treatment for mild to moderate pain in patients with CKD. This supports the citing sentence’s description of it as a mainstay analgesic option. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“No robust evidence supports an association between paracetamol and adverse cardiovascular outcomes (stroke or myocardial infarction) in patients with atherosclerotic heart diseases.94–96”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Potential Clinical Consequences of the Centrally Located Analgesic Action of Paracetamol > Paracetamol, a COX-Independent, Centrally Acted as the First Choice for a Wide Range of Special Populations
What the sources say
- Supportedcites [94] White, 2018, J Cardiovasc Pharmacol Ther source
The Cardiovascular Events From Clinical Trials section says no randomized trial of OTC acetaminophen was adequate to assess cardiovascular risk. In Patients With Hypertension, the review reports that a short trial in patients with coronary artery disease observed no cardiovascular events. This supports the claim about a lack of robust event evidence in that patient group, not a conclusion that acetaminophen is risk-free. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [95] Dawson, 2013, J Hypertens source
- Not checked — no full text of the sourcecites [96] Fulton, 2015, Hypertension source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, several molecular actors targeted by the bioactive AM404, including the Cav3.2 calcium channel, the cannabinoid CB1 receptors and TRPV1 receptors, would participate in the MoA.10,20,21”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Introduction
What the sources say
- Partly supportedcites [10] Ohashi, 2020, Front Pharmacol sourceExperimental — accuracy not yet measured
The ‘Activating the Transient Receptor Potential Vanilloid 1 and Cannabinoid 1 Receptors’ section describes AM404 acting on TRPV1 and CB1 receptors in acetaminophen analgesia, although it reports no CB1-mediated effect in the spinal dorsal horn at the dose studied. Neither that section nor the analgesic-mechanisms table identifies Cav3.2 as an AM404 target or participant in the mechanism. (LLM, conf=0.87)
- Partly supportedcites [20] Muramatsu, 2016, Anesthesiol Pain Med sourceExperimental — accuracy not yet measured
The Background (page not provided) identifies AM404 as an activator of TRPV1 and a ligand at cannabinoid CB1 receptors. The Discussion (page not provided) says brain TRPV1 may be involved in acetaminophen’s antinociceptive action. Our copy does not mention Cav3.2, so it does not support that part of the claim. (LLM, conf=0.88)
- Partly supportedcites [21] Saliba, 2017, J Neuroinflammation sourceExperimental — accuracy not yet measured
The Background (page unavailable) identifies AM404 as a paracetamol metabolite that acts on TRPV1 and binds CB1, and suggests AM404 may contribute to paracetamol’s analgesic mechanism. Our copy does not identify Cav3.2 as an AM404 target or participant in that mechanism. The Results and Discussion (page unavailable) also find that AM404’s anti-inflammatory effect in microglia is independent of CB1 and TRPV1; that narrower finding does not rule out their participation in other effects. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
56 more claims · 12 with their cited sources checked
Create a free account to see all 106 claims and to verify the 12 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 14
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > AM404: The Active Metabolite of Paracetamol
“Importantly, it has been shown that 1) centrally injected AM404 induced analgesia37,44,45”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > References
“44. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008; 26(5): 778– 785.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Potential Clinical Consequences of the Centrally Located Analgesic Action of Paracetamol > Paracetamol in Combination with Other Analgesics
“Experimental evidence showed that paracetamol had a synergistic effect on gabapentin.126”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > References
“126. Mititelu Tartau L, Popa EG, Lupusoru RV, Lupusoru CE, Stoleriu I, Ochiuz L. Synergic effects of pregabalin-acetaminophen combination in somatic and visceral nociceptive reactivity.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Potential Clinical Consequences of the Centrally Located Analgesic Action of Paracetamol > Paracetamol in Combination with Other Analgesics
“However, a 13-week trial showed patients on paracetamol/ibuprofen combination had a higher risk of decreases in hemoglobin level (≥1 g/dl) than monotherapy, suggesting a potential risk of bleeding on long-term use of paracetamol/ibuprofen combination.122”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Potential Clinical Consequences of the Centrally Located Analgesic Action of Paracetamol > Paracetamol in Combination with Other Analgesics
“| Daniels et al, 2011122 | Dental | Double-blind RCT | 678 | Ibuprofen/Paracetamol 400 mg/1000 mgIbuprofen/Paracetamol 200 mg/500 mgIbuprofen/Codeine 400 mg/25.6 mgCodeine/ Paracetamol 30 mg/1000 mgPlacebo | Single dose, postoperative |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > AM404-Modulated Molecular Targets > Downstream Targets of TRPV1
“In 2014, Kerckhove et al demonstrated that Cav3.2 knockout mice had impaired response to the analgesic effect of a systemic administration of paracetamol or intracerebroventricular injection of AM404.55”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > References
“55. Barbara G, Alloui A, Nargeot J, et al. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J Neurosci. 2009; 29(42): 13106– 13114.”
Citations
Cites
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989 · cited 1×
“COX-3 is an exon splice variant from COX-1 that was identified in the canine cerebral cortex and exhibited selective sensitivity to paracetamol.(34) However, further genomic and kinetic studies showed that a full-length, catalytically active form of COX-3 does not exist in humans(35,36) and that the COX-3 selective in…”
BackgroundRastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Murakami, M., Naraba, H., Tanioka, T., Semmyo, N., Nakatani, Y., Kojima, F., Ikeda, T., Fueki, M., Ueno, A., Oh-ishi, S., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003505200 · Cited by 964
Descending control of nociception: Specificity, recruitment and plasticity
Heinricher, M. M., Tavares, I., Leith, J. L., & Lumb, B. M. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.009 · Cited by 949 · cited 1×
“Serotonin appears to have both inhibitory and facilitative effects on pain.(58) The involvement of the serotonergic pathway in the analgesic effect of paracetamol was described even before the 2005 work by Högestätt et al.”
BackgroundAntman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804 · cited 1×
“According to an American Heart Association position statement, paracetamol should be preferred over NSAIDs in patients with coronary artery disease.(100) Aspirin and other NSAIDs significantly increase the risk of gastrointestinal ulcers and bleeding.”
BackgroundFLOWER, R. J., & VANE, J. R. (1972) · Nature · doi:10.1038/240410a0 · Cited by 779 · cited 2×
“Flower and Vane demonstrated that the COX inhibitory effect of paracetamol was more potent in the brain than in the spleen, suggesting another COX isoenzyme as a sensitive site for paracetamol action.(8) COX-3 is an exon splice variant from COX-1 that was identified in the canine cerebral cortex and exhibited selectiv…”
BackgroundParacetamol: New Vistas of an Old Drug
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00250.x · Cited by 674 · cited 1×
“Despite its wide use, debate exists regarding the analgesic mechanism of action (MoA) of paracetamol.(7) Historically, it was believed that the paracetamol-mediated analgesia stems solely from its cyclooxygenase (COX)dependent inhibitory effect on prostaglandin (PG) synthesis(8); however, it is now evident that the an…”
BackgroundGraham, G. G., Davies, M. J., Day, R. O., Mohamudally, A., & Scott, K. F. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0172-x · Cited by 671
Mechanism of Action of Paracetamol
Graham, G. G., & Scott, K. F. (2005) · American Journal of Therapeutics · doi:10.1097/00045391-200501000-00008 · Cited by 648 · cited 1×
“However, further genomic and kinetic studies showed that a full-length, catalytically active form of COX-3 does not exist in humans(35,36) and that the COX-3 selective interaction is unlikely to be clinically relevant.(31) However, the question remained whether the analgesic MoA of paracetamol is primarily mediated by…”
BackgroundOng, C. K. S., Seymour, R. A., Lirk, P., & Merry, A. F. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181cf9281 · Cited by 631 · cited 2×
“In a previous systematic review, combining paracetamol and NSAIDs was more effective than either agent alone in acute postoperative pain.(115) The antinociceptive effects derived from paracetamol/NSAIDs combinations appear to be additive rather than synergistic; in 2012, Moore et al demonstrated that paracetamol plus…”
BackgroundResultTreatment of acute postoperative pain
Wu, C. L., & Raja, S. N. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60245-6 · Cited by 628
Högestätt, E. D., Jönsson, B. A. G., Ermund, A., Andersson, D. A., Björk, H., Alexander, J. P., Cravatt, B. F., Basbaum, A. I., & Zygmunt, P. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501489200 · Cited by 454 · cited 2×
“In this report, Högestätt et al demonstrated that the deacetylated form of paracetamol, the p-aminophenol, is converted mainly in the brain to AM404 by the fatty acid amide hydrolase (FAAH) enzyme (Figure 1).(16) These findings were then supported by Muramatsu et al’s experiment.”
BackgroundMethodInfluential(2014) · PubMed · Cited by 390
Cardiovascular effects and safety of (non-aspirin) NSAIDs
Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0366-z · Cited by 387 · cited 5×
“The current evidence affirms the more tolerable gastrointestinal safety profile of paracetamol than NSAIDs.101 Thus, paracetamol is the recommended first-line option for patients at risk of gastrointestinal ulcers or bleeding.6 Finally, paracetamol is considered the preferred analgesic option for the elderly, a challe…”
BackgroundInfluentialPharmacology of oral combination analgesics: rational therapy for pain
Raffa, R. B. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00355.x · Cited by 284
Analgesic effect of acetaminophen in humans: First evidence of a central serotonergic mechanism
PICKERING, G., LORIOT, M., LIBERT, F., ESCHALIER, A., BEAUNE, P., & DUBRAY, C. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.12.307 · Cited by 283
Self-citationThe analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors
Ottani, A., Leone, S., Sandrini, M., Ferrari, A., & Bertolini, A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.015 · Cited by 279 · cited 1×
“In the setting of paracetamol injection, CB1 knockout models or mice pretreated with selective CB1 antagonists showed no analgesic response to paracetamol.(17,56) The expected synergism between paracetamol and opiates was also attenuated in mice pretreated with selective CB1 antagonist.”
BackgroundThe anandamide transport inhibitor AM404 activates vanilloid receptors
Zygmunt, P. M., Chuang, H.-H., Movahed, P., Julius, D., & Högestätt, E. D. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00207-7 · Cited by 270 · cited 1×
“In Zygmunt et al’s patch-clamp experiment, AM404 activated the vanilloid receptor TRPV1, an effect that was suppressed after administration of the TRPV1 antagonist, capsazepine.(49) Besides, experiments showed diminished analgesic action of paracetamol and p-aminophenol in TRPV1 knockout mice and mice pretreated with…”
BackgroundO'Neil, C. K., Hanlon, J. T., & Marcum, Z. A. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.09.004 · Cited by 261 · cited 1×
“The good tolerability at the recommended dosage (eg, lack of gastrointestinal adverse effects) is a major contributor to the preference for paracetamol by general practitioners, specialists, and pharmacists.(3) Although it was introduced in clinics more than 100 years ago,(4) paracetamol remains the recommended first-…”
BackgroundCombination pharmacotherapy for management of chronic pain: from bench to bedside
Gilron, I., Jensen, T. S., & Dickenson, A. H. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70193-5 · Cited by 240
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia
Mallet, C., Daulhac, L., Bonnefont, J., Ledent, C., Etienne, M., Chapuy, E., Libert, F., & Eschalier, A. (2008) · Pain · doi:10.1016/j.pain.2008.03.030 · Cited by 223 · cited 2×
“Importantly, it has been shown that 1) centrally injected AM404 induced analgesia(37,44,45) and 2) the inhibition of FAAH (genetically and pharmacologically) suppressed the analgesic effect of paracetamol (and p-aminophenol), demonstrating the involvement of AM404 as the active metabolite in the analgesic effect of pa…”
BackgroundSelf-citationAnalgesic Effect of Acetaminophen: A Review of Known and Novel Mechanisms of Action
Ohashi, N., & Kohno, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580289 · Cited by 223 · cited 5×
“Theoretically, combining two analgesics with different mechanisms of action potentiates their analgesic actions without increasing their doses and compromising the safety outcomes.103–106 Paracetamol has linear and consistent pharmacokinetics, and its tolerable profile makes it a good option when a combination is requ…”
BackgroundInfluentialParacetamol (acetaminophen): A familiar drug with an unexplained mechanism of action
Ayoub, S. S. (2021) · Temperature · doi:10.1080/23328940.2021.1886392 · Cited by 223
ARONOFF, D., OATES, J., & BOUTAUD, O. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.009 · Cited by 222
Boutaud, O., Aronoff, D. M., Richardson, J. H., Marnett, L. J., & Oates, J. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102588199 · Cited by 209
Paracetamol: A Review of Guideline Recommendations
Freo, U., Ruocco, C., Valerio, A., Scagnol, I., & Nisoli, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153420 · Cited by 208 · cited 2×
“Although it was introduced in clinics more than 100 years ago,(4) paracetamol remains the recommended first-line option for pain management by several scientific societies, and particularly in vulnerable populations such as geriatrics, children, patients with peptic ulcers, and pregnant women.(5,6) Despite its wide us…”
BackgroundPyrogen fever and prostaglandin‐like activity in cerebrospinal fluid
Feldberg, W., & Gupta, K. P. (1973) · The Journal of Physiology · doi:10.1113/jphysiol.1973.sp010071 · Cited by 205
Paracetamol – An old drug with new mechanisms of action
Przybyła, G. W., Szychowski, K. A., & Gmiński, J. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13392 · Cited by 190 · cited 4×
“As we have elucidated in this article, paracetamol itself can be considered as a pro-drug of the active centrally located metabolite, AM404.”
BackgroundInfluentialSynergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain
Miranda, H. F., Puig, M. M., Prieto, J. C., & Pinardi, G. (2006) · Pain · doi:10.1016/j.pain.2005.11.012 · Cited by 186
Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews
Moore, R. A., Wiffen, P. J., Derry, S., Maguire, T., Roy, Y. M., & Tyrrell, L. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010794.pub2 · Cited by 174 · cited 1×
“In terms of safety, a Cochrane review concluded that the rate of adverse events was similar between the higher and lower single doses of paracetamol.(84) This was in line with another clinical trial showing similar rates of treatment-related adverse events between the higher and lower single doses of paracetamol.”
ResultSingle dose oral ibuprofen plus paracetamol (acetaminophen) for acute postoperative pain
Derry, C. J., Derry, S., & Moore, R. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010210.pub2 · Cited by 173 · cited 1×
“In a 2013 Cochrane review over three trials (n = 1647 patients), paracetamol/ibuprofen combination demonstrated higher reductions in acute postoperative pain and fewer patients needed rescue analgesia than either drug alone in patients undergoing impacted third molars extraction.(119) These findings align with the 201…”
ResultDahl, J. B., Nielsen, R. V., Wetterslev, J., Nikolajsen, L., Hamunen, K., Kontinen, V., HANSEN, M. S., Kjer, J. J., Mathiesen, O., & Scandinavian Postoperative Pain Alliance (ScaPAlli) (2014) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12382 · Cited by 173 · cited 1×
“Paracetamol can theoretically potentiate the analgesic and morphine-sparing effects of NSAIDs in patients with acute pain without the need to increase NSAIDs doses.(113,114) In a previous systematic review, combining paracetamol and NSAIDs was more effective than either agent alone in acute postoperative pain.”
BackgroundAcetaminophen Reinforces Descending Inhibitory Pain Pathways
Pickering, G., Estève, V, Loriot, M.-A., Eschalier, A., & Dubray, C. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100403 · Cited by 168
Self-citationMechanism of Acetaminophen Inhibition of Cyclooxygenase Isoforms
Ouellet, M., & Percival, M. D. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.2232 · Cited by 166
TRPV1 in Brain Is Involved in Acetaminophen-Induced Antinociception
Mallet, C., Barrière, D. A., Ermund, A., Jönsson, B. A. G., Eschalier, A., Zygmunt, P. M., & Högestätt, E. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012748 · Cited by 165 · cited 9×
“In mice, administering a weekly dose of paracetamol, which induced an analgesic effect, did not reduce PGE2 content in the brain.(37) Besides, the antinociceptive profile of paracetamol was found to be different from that of the competitive COX inhibitor, ibuprofen, with no observed antinociceptive action of ibuprofen…”
BackgroundInfluentialSelf-citationAntinociceptive effect of paracetamol in rats is partly dependent on spinal serotonergic systems
Tjølsen, A., Lund, A., & Hole, K. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90036-p · Cited by 163 · cited 2×
“Serotonin appears to have both inhibitory and facilitative effects on pain.58 The involvement of the serotonergic pathway in the analgesic effect of paracetamol was described even before the 2005 work by Högestätt et al.59 Earlier reports described the pharmacological blockade of the serotonergic pathway decreased the…”
BackgroundInfluentialThybo, K. H., Hägi-Pedersen, D., Dahl, J. B., Wetterslev, J., Nersesjan, M., Jakobsen, J. C., Pedersen, N. A., Overgaard, S., Schrøder, H. M., Schmidt, H., et al. (2019) · JAMA · doi:10.1001/jama.2018.22039 · Cited by 142 · cited 2×
“Recently, the PANSAID trial showed paracetamol/ibuprofen combination achieved higher analgesia and morphine-sparing effect than paracetamol alone in the first 24 hours after total hip arthroplasty.(120) The benefit of the paracetamol/ibuprofen combination was not significantly influenced by age, sex, or type of anesth…”
BackgroundRahme, E., Barkun, A., Nedjar, H., Gaugris, S., & Watson, D. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01811.x · Cited by 138 · cited 1×
“A population-based retrospective cohort study, using data from the government of Quebec health insurance agency databases, suggested that combining traditional NSAIDs with acetaminophen increases the risk of upper GI events beyond that of either agent alone.(125) Even if one of the limitations of this study pertains t…”
MethodToussaint, K., Yang, X. C., Zielinski, M. A., Reigle, K. L., Sacavage, S. D., Nagar, S., & Raffa, R. B. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01143.x · Cited by 135
François, A., Kerckhove, N., Méleine, M., Alloui, A., Barr�re, C., Gelot, A., Uebele, V. N., Renger, J. J., Eschalier, A., Ardid, D., et al. (2012) · Pain · doi:10.1016/j.pain.2012.10.023 · Cited by 133 · cited 1×
“2 blockers showed impaired nociceptive response to pain stimuli.(54) Previous reports indicated that the antinociceptive action of arachidonic compounds involves inhibition of Cav3.”
BackgroundSelf-citationAcetaminophen for Chronic Pain: A Systematic Review on Efficacy
Ennis, Z. N., Dideriksen, D., Vægter, H. B., Handberg, G., & Pottegård, A. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12527 · Cited by 129 · cited 1×
“Globally, paracetamol is also at the apex of the most commonly utilized over-the-counter (OTC) analgesic and the preferred first-line option for patients with mild-tomoderate acute pain.(2) The good tolerability at the recommended dosage (eg, lack of gastrointestinal adverse effects) is a major contributor to the pref…”
BackgroundCellular mechanisms of acetaminophen: role of cyclo‐oxygenase
Lucas, R., Warner, T. D., Vojnovic, I., & Mitchell, J. A. (2005) · The FASEB Journal · doi:10.1096/fj.04-2437fje · Cited by 128
Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure
Davison, S. N. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05180418 · Cited by 127 · cited 1×
“Regarding kidney function, NSAIDs, inhibitors of COX, should be avoided in patients with renal impairment.(88) On the contrary, therapeutic doses of paracetamol are generally safe and do not lead to acute renal failure in patients with renal impairment.”
BackgroundT-Type Calcium Channel Inhibition Underlies the Analgesic Effects of the Endogenous Lipoamino Acids
Barbara, G., Alloui, A., Nargeot, J., Lory, P., Eschalier, A., Bourinet, E., & Chemin, J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2919-09.2009 · Cited by 125 · cited 4×
“As we have elucidated in this article, paracetamol itself can be considered as a pro-drug of the active centrally located metabolite, AM404.”
BackgroundInfluentialSelf-citationT-type calcium channels in neuropathic pain
Bourinet, E., François, A., & Laffray, S. (2015) · Pain · doi:10.1097/j.pain.0000000000000469 · Cited by 115 · cited 1×
“2 isoform regulates the neuronal response to pain.(52,53) Cav3.”
BackgroundSNIEZEK, P. J., BRODLAND, D. G., & ZITELLI, J. A. (2011) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2011.02022.x · Cited by 114
Ayoub, S. S., Botting, R. M., Goorha, S., Colville-Nash, P. R., Willoughby, D. A., & Ballou, L. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404185101 · Cited by 104
Can paracetamol (acetaminophen) be administered to patients with liver impairment?
Hayward, K. L., Powell, E. E., Irvine, K. M., & Martin, J. H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12802 · Cited by 104 · cited 1×
“Paracetamol-related adverse events are rare in healthy adults receiving a daily dose of ≤4 g/day.(77) Thus, several guidelines recommend paracetamol as an optimal option for mild-to-moderate pain conditions, such as headache and migraine attacks, postoperative pain and chronic osteoarthritis for limited duration of tr…”
BackgroundMcQuay, H. J., & Moore, R. A. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02723.x · Cited by 101
COX-3: in the wrong frame in mind
Dinchuk, J. E., Liu, R. Q., & Trzaskos, J. M. (2003) · Immunology Letters · doi:10.1016/s0165-2478(02)00268-7 · Cited by 100
Modification of anti-inflammatory drug effectiveness by ambient lipid peroxides
Hanel, A. M., & Lands, W. E. M. (1982) · Biochemical Pharmacology · doi:10.1016/0006-2952(82)90565-2 · Cited by 95
Daniels, S. E., Goulder, M. A., Aspley, S., & Reader, S. (2011) · Pain · doi:10.1016/j.pain.2010.12.012 · Cited by 87 · cited 1×
“However, a 13-week trial showed patients on paracetamol/ibuprofen combination had a higher risk of decreases in hemoglobin level (≥1 g/dl) than monotherapy, suggesting a potential risk of bleeding on long-term use of paracetamol/ibuprofen combination.(122) A population-based retrospective cohort study, using data from…”
BackgroundDogrul, A., Seyrek, M., Akgul, E. O., Cayci, T., Kahraman, S., & Bolay, H. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.016 · Cited by 83
Alloui, A., Chassaing, C., Schmidt, J., Ardid, D., Dubray, C., Cloarec, A., & Eschalier, A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01578-9 · Cited by 83
Self-citationFricke, J. R., Karim, R., Jordan, D. M., & Rosenthal, N. R. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80010-8 · Cited by 83
Central and peripheral contributions of T-type calcium channels in pain
Harding, E. K., & Zamponi, G. W. (2022) · Molecular Brain · doi:10.1186/s13041-022-00923-w · Cited by 82 · cited 1×
“2 isoform regulates the neuronal response to pain.(52,53) Cav3.”
BackgroundBonnefont, J., Chapuy, E., Clottes, E., Alloui, A., & Eschalier, A. (2005) · Pain · doi:10.1016/j.pain.2005.01.019 · Cited by 81
Self-citationRegular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial
MacIntyre, I. M., Turtle, E. J., Farrah, T. E., Graham, C., Dear, J. W., Webb, D. J., McCallum, M., Melville, V., Fok, H., McCrae, J. C., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056015 · Cited by 80 · cited 1×
“On the other hand, the risk of worsening hypertension should be considered, with some observational studies showing an increase in blood pressure among chronic paracetamol users.(97,98) Still, published studies failed to show an association between elevated blood pressure and the risk of serious cardiovascular events…”
BackgroundCombination analgesia in 2005—a rational approach: focus on paracetamol–tramadol
Schug, S. A. (2006) · Clinical Rheumatology · doi:10.1007/s10067-006-0202-9 · Cited by 80 · cited 1×
“The paracetamol plus opioids combination can benefit from the rapid onset of action of paracetamol and the sustained analgesic effect of opioids.(108) Several reports demonstrated that paracetamol plus opioids led to superior pain relief and lower dose requirements than individual components without”
BackgroundEffects of acetaminophen on monoaminergic systems in the rat central nervous system
Courade, J.-P., Caussade, F., Martin, K., Besse, D., Delchambre, C., Hanoun, N., Hamon, M., Eschalier, A., & Cloarec, A. (2001) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100100484 · Cited by 79
Self-citationHaag, G., Diener, H.-C., May, A., Meyer, C., Morck, H., Straube, A., Wessely, P., & Evers, S. (2011) · The Journal of Headache and Pain · doi:10.1007/s10194-010-0266-4 · Cited by 78
Dhillon, S. (2010) · Clinical Drug Investigation · doi:10.2165/11205830-000000000-00000 · Cited by 78
Lack of acetaminophen ceiling effect on R-III nociceptive flexion reflex
Piguet, V., Desmeules, J. A., & Dayer, P. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050386 · Cited by 77 · cited 1×
“This observation is consistent with the successful experimental demonstration in healthy volunteers of a lack of acetaminophen ceiling effect on R-III nociceptive flexion reflex.(83) In terms of safety, a Cochrane review concluded that the rate of adverse events was similar between the higher and lower single doses of…”
ResultSelf-citationBonnefont, J., Alloui, A., Chapuy, E., Clottes, E., & Eschalier, A. (2003) · Anesthesiology · doi:10.1097/00000542-200310000-00034 · Cited by 74
Self-citationAcetaminophen, aspirin and progression of advanced chronic kidney disease
Evans, M., Fored, C. M., Bellocco, R., Fitzmaurice, G. M., Fryzek, J. P., McLaughlin, J. K., Nyrén, O., & Elinder, C. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn745 · Cited by 73 · cited 1×
“It was previously hypothesized that paracetamol may cause renal injury due to the reports of nephropathy after phenacetin overuse; however, this hypothesis was then rejected by further evidence.(90) Data show no association between paracetamol and acute renal failure in patients with chronic kidney disease.”
ResultBannwarth, B., & P??hourcq, F. (2003) · Drugs · doi:10.2165/00003495-200363992-00003 · Cited by 71
Acetaminophen reduces lipopolysaccharide-induced fever by inhibiting cyclooxygenase-2
Engström Ruud, L., Wilhelms, D. B., Eskilsson, A., Vasilache, A. M., Elander, L., Engblom, D., & Blomqvist, A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.012 · Cited by 70
Combination tramadol plus acetaminophen for postsurgical pain
Smith, A. B., Ravikumar, T. S., Kamin, M., Jordan, D. M., Xiang, J. X., & Rosenthal, N. R. (2004) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2003.12.038 · Cited by 69
Martín Arias, L. H., Martín González, A., Sanz Fadrique, R., & Vazquez, E. S. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1302 · Cited by 68 · cited 1×
“NSAIDs significantly increase the risk of cardiovascular adverse outcomes.(93) No robust evidence supports an association between paracetamol and adverse cardiovascular outcomes (stroke or myocardial infarction) in patients with atherosclerotic heart diseases.”
BackgroundCav3.2 calcium channels: The key protagonist in the supraspinal effect of paracetamol
Kerckhove, N., Mallet, C., François, A., Boudes, M., Chemin, J., Voets, T., Bourinet, E., Alloui, A., & Eschalier, A. (2014) · Pain · doi:10.1016/j.pain.2014.01.015 · Cited by 65 · cited 5×
“2 acting downstream of TRPV1.”
BackgroundInfluentialSelf-citationAlchin, J., Dhar, A., Siddiqui, K., & Christo, P. J. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2049551 · Cited by 65 · cited 5×
“It is unnecessary to modify the dose for dialytic patients; however, dose reduction or longer dose interval should be considered in patients with advanced kidney failure.(6) NSAIDs significantly increase the risk of cardiovascular adverse outcomes.”
BackgroundInfluentialImpact of acetaminophen on the efficacy of immunotherapy in cancer patients
Bessede, A., Marabelle, A., Guégan, J., Danlos, F., Cousin, S., Peyraud, F., Chaput, N., Ceruso, M. S., Roubaud, G., Cabart, M., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.010 · Cited by 64 · cited 1×
“In another context, a recent work suggests that acetaminophen would be a potential suppressor of antitumor immunity, suggesting that it should be used with caution in patients treated with immune checkpoint blockers.(87) Regarding kidney function, NSAIDs, inhibitors of COX, should be avoided in patients with renal imp…”
BackgroundToxicological Property of Acetaminophen: The Dark Side of a Safe Antipyretic/Analgesic Drug?
Ishitsuka, Y., Kondo, Y., & Kadowaki, D. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00722 · Cited by 63 · cited 5×
“The current evidence affirms the more tolerable gastrointestinal safety profile of paracetamol than NSAIDs.101 Thus, paracetamol is the recommended first-line option for patients at risk of gastrointestinal ulcers or bleeding.6 Finally, paracetamol is considered the preferred analgesic option for the elderly, a challe…”
BackgroundInfluentialMoore, R. A., Derry, C. J., Derry, S., Straube, S., & McQuay, H. J. (2012) · European Journal of Pain · doi:10.1016/j.ejpain.2011.08.009 · Cited by 63 · cited 1×
“The antinociceptive effects derived from paracetamol/NSAIDs combinations appear to be additive rather than synergistic; in 2012, Moore et al demonstrated that paracetamol plus NSAIDs led to additive analgesic rather than supra-additive (ie, synergism) effects.(116) Previous pharmacokinetic reports demonstrated the lac…”
BackgroundBarrière, D. A., Mallet, C., Blomgren, A., Simonsen, C., Daulhac, L., Libert, F., Chapuy, E., Etienne, M., Högestätt, E. D., Zygmunt, P. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070690 · Cited by 62 · cited 3×
“Importantly, it has been shown that 1) centrally injected AM404 induced analgesia(37,44,45) and 2) the inhibition of FAAH (genetically and pharmacologically) suppressed the analgesic effect of paracetamol (and p-aminophenol), demonstrating the involvement of AM404 as the active metabolite in the analgesic effect of pa…”
BackgroundSelf-citationSaliba, S. W., Marcotegui, A. R., Fortwängler, E., Ditrich, J., Perazzo, J. C., Muñoz, E., de Oliveira, A. C. P., & Fiebich, B. L. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1014-3 · Cited by 62 · cited 5×
“Theoretically, combining two analgesics with different mechanisms of action potentiates their analgesic actions without increasing their doses and compromising the safety outcomes.103–106 Paracetamol has linear and consistent pharmacokinetics, and its tolerable profile makes it a good option when a combination is requ…”
BackgroundInfluentialMitchell, A., McCrea, P., Inglis, K., & Porter, G. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2447-7 · Cited by 61
Hama, A. T., & Sagen, J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.010 · Cited by 61 · cited 1×
“The expected synergism between paracetamol and opiates was also attenuated in mice pretreated with selective CB1 antagonist.(57) Notably, two previous reports showed that paracetamol injection did not alter the brain endocannabinoid content, suggesting that other studies are needed to know how CB1 receptors are involv…”
BackgroundTRPV1 and Endocannabinoids: Emerging Molecular Signals that Modulate Mammalian Vision
Ryskamp, D., Redmon, S., Jo, A., & Križaj, D. (2014) · Cells · doi:10.3390/cells3030914 · Cited by 60
Durmus, M., Kadir But, A., Saricicek, V., Ilksen Toprak, H., & Ozcan Ersoy, M. (2007) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2006.01237.x · Cited by 60 · cited 1×
“The results showed that the paracetamol and gabapentin combination was superior to gabapentin alone on pain intensity scores.(127) Further investigations are warranted.”
ResultCOX‐3—a virtual pain target in humans?
Schwab, J. M., Beiter, T., Linder, J. U., Laufer, S., Schulz, J. E., Meyermann, R., & Schluesener, H. J. (2003) · The FASEB Journal · doi:10.1096/fj.03-0595lte · Cited by 59
Safety of Nonsteroidal Antiinflammatory Drugs in Patients with Cardiovascular Disease
Danelich, I. M., Wright, S. S., Lose, J. M., Tefft, B. J., Cicci, J. D., & Reed, B. N. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1584 · Cited by 58 · cited 1×
“Most NSAIDs have safety concerns related to the development of gastric ulcers and bleeding, bronchial asthma, acute kidney injury, and long-term adverse cardiovascular outcomes.(75) Initial reports classified paracetamol as a part of the NSAIDs class due to the presumably shared inhibitory effect on PG synthesis.”
BackgroundAcetaminophen inhibits prostanoid synthesis by scavenging the PGHS‐activator peroxynitrite
Schildknecht, S., Daiber, A., Ghisla, S., Cohen, R. A., & Bachschmid, M. M. (2008) · The FASEB Journal · doi:10.1096/fj.06-8015com · Cited by 57
Liao, H., Lee, H., Ho, Y., & Chiou, L. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01214.x · Cited by 56 · cited 1×
“Contrary to the periphery, where activated TRPV1 induces nociception, hyperalgesia, and pain transduction modulation,(47) supraspinal TRPV1 activation induces anti-nociception.(37,45,48) In Zygmunt et al’s patch-clamp experiment, AM404 activated the vanilloid receptor TRPV1, an effect that was suppressed after adminis…”
BackgroundThe pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol
Tanner, T., Aspley, S., Munn, A., & Thomas, T. (2010) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-10-10 · Cited by 51 · cited 1×
“Previous pharmacokinetic reports demonstrated the lack of significant interactions in the pharmacokinetic profiles of ibuprofen and paracetamol when administered in a fixed-dose combination tablet, highlighting that the effect of this combination is primarily a pharmacodynamic one.(117,118) Thus, the paracetamol/ibupr…”
BackgroundFirst evidence of the conversion of paracetamol to AM404 in human cerebrospinal fluid
Sharma, C., Long, J. H., Shah, S., Rahman, J., Perrett, D., Ayoub, S., & Mehta, V. (2017) · Journal of Pain Research · doi:10.2147/jpr.s143500 · Cited by 51 · cited 1×
“The study detected AM404 in the CSF of 17 patients, confirming the central conversion of paracetamol to the bioactive AM404 in humans.(43) Importantly, it has been shown that 1) centrally injected AM404 induced analgesia(37,44,45) and 2) the inhibition of FAAH (genetically and pharmacologically) suppressed the analges…”
BackgroundOpioid receptors and acetaminophen (paracetamol)
Raffa, R. B., Walker, E. A., & Sterious, S. N. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.08.055 · Cited by 49 · cited 1×
“Historically, it was believed that the paracetamol-mediated analgesia stems solely from its cyclooxygenase (COX)dependent inhibitory effect on prostaglandin (PG) synthesis(8); however, it is now evident that the analgesic MoA of paracetamol is multidimensional and involves several pathways within the central nervous s…”
BackgroundTurtle, E. J., Dear, J. W., & Webb, D. J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12032 · Cited by 48 · cited 1×
“On the other hand, the risk of worsening hypertension should be considered, with some observational studies showing an increase in blood pressure among chronic paracetamol users.(97,98) Still, published studies failed to show an association between elevated blood pressure and the risk of serious cardiovascular events…”
BackgroundMacleod, A. W. G., Ashford, B., Voltz, M. J., Williams, B., Cramond, T., Gorta, L., & Simpson, J. (2002) · Australian Dental Journal · doi:10.1111/j.1834-7819.2002.tb00319.x · Cited by 47
Graham, G., Graham, R., & Day, R. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023394917 · Cited by 46 · cited 1×
“Data show no association between paracetamol and acute renal failure in patients with chronic kidney disease.(91) Thus, paracetamol remains the mainstay analgesic option in patients with chronic kidney disease.”
BackgroundParacetamol for Multimodal Analgesia
Freo, U. (2022) · Pain Management · doi:10.2217/pmt-2021-0116 · Cited by 46 · cited 1×
“However, we do not have good evidence that paracetamol spares the opioid adverse effects when a high dose of opioid is used.(111) Recently, a comparative trial showed that the oxycodone/paracetamol combination was more effective than celecoxib in terms of reducing postoperative pain and rescue analgesia consumption am…”
Background[Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues].
Bannwarth, B., & Péhourcq, F. (2003) · PubMed · Cited by 45
Mirrasekhian, E., Nilsson, J. L. Å., Shionoya, K., Blomgren, A., Zygmunt, P. M., Engblom, D., Högestôtt, E. D., & Blomqvist, A. (2018) · The FASEB Journal · doi:10.1096/fj.201800272r · Cited by 44
Tropisetron blocks analgesic action of acetaminophen: A human pain model study
Bandschapp, O., Filitz, J., Urwyler, A., Koppert, W., & Ruppen, W. (2011) · Pain · doi:10.1016/j.pain.2011.02.003 · Cited by 41
Bonnefont, J., Daulhac, L., Etienne, M., Chapuy, E., Mallet, C., Ouchchane, L., Deval, C., Courade, J.-P., Ferrara, M., Eschalier, A., et al. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.025775 · Cited by 39
Self-citationOhashi, N., Uta, D., Sasaki, M., Ohashi, M., Kamiya, Y., & Kohno, T. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001700 · Cited by 39
Rawal, N., Macquaire, Catalá, Berti, M., Costa, & Wietlisbach, M. (2011) · Journal of Pain Research · doi:10.2147/jpr.s16760 · Cited by 39
Liu, J., Reid, A. R., & Sawynok, J. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2012.12.052 · Cited by 38
Pharmacological hypotheses: Is acetaminophen selective in its cyclooxygenase inhibition?
Esh, C. J., Chrismas, B. C. R., Mauger, A. R., & Taylor, L. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.835 · Cited by 38
Neuropharmacological basis for multimodal analgesia in chronic pain
Patel, R., & Dickenson, A. H. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1985351 · Cited by 38
Alloui, A., Pelissier, T., Dubray, C., Lavarenne, J., & Eschalier, A. (1996) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1996.tb00593.x · Cited by 36
Self-citationHiragi, S., Yamada, H., Tsukomoto, T., Yoshida, K., Kondo, N., Matsubara, T., Yanagita, M., Tamura, H., & Kuroda, T. (2018) · Clinical Epidemiology · doi:10.2147/clep.s158110 · Cited by 35 · cited 1×
“On the contrary, therapeutic doses of paracetamol are generally safe and do not lead to acute renal failure in patients with renal impairment.(89) It was previously hypothesized that paracetamol may cause renal injury due to the reports of nephropathy after phenacetin overuse; however, this hypothesis was then rejecte…”
BackgroundAcetaminophen Use and Risk of Myocardial Infarction and Stroke in a Hypertensive Cohort
Fulton, R. L., Walters, M. R., Morton, R., Touyz, R. M., Dominiczak, A. F., Morrison, D. S., Padmanabhan, S., Meredith, P. A., McInnes, G. T., & Dawson, J. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04945 · Cited by 35 · cited 1×
“Still, published studies failed to show an association between elevated blood pressure and the risk of serious cardiovascular events in paracetamol users.(96) Paracetamol remains probably safer than NSAIDs which showed a significant increase in adverse cardiovascular outcomes amongst patients receiving non-aspirin NSA…”
ResultParacetamol is a centrally acting analgesic using mechanisms located in the periaqueductal grey
Barrière, D. A., Boumezbeur, F., Dalmann, R., Cadeddu, R., Richard, D., Pinguet, J., Daulhac, L., Sarret, P., Whittingstall, K., Keller, M., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14934 · Cited by 34 · cited 1×
“Recently, periaqueductal grey-located CB1 receptors were found to be essential for the MoA of paracetamol through a AM404-activated TRPV1 channel-mGlu5 receptor-PLC-DAGL-CB1 receptor signaling.(50) Serotonin (5-HT) and norepinephrine are engaged in pathways of physiological nociception, both of which can be produced v…”
BackgroundSelf-citationJebaraj, B., Maitra, S., Baidya, D. K., & Khanna, P. (2013) · Pain Research and Treatment · doi:10.1155/2013/402510 · Cited by 33 · cited 1×
“increasing the risk of adverse events in a wide range of pain conditions, such as osteoarthritis and postoperative pain.(109,110) However, we do not have good evidence that paracetamol spares the opioid adverse effects when a high dose of opioid is used.”
BackgroundSupra-spinal FAAH is required for the analgesic action of paracetamol in an inflammatory context
Dalmann, R., Daulhac, L., Antri, M., Eschalier, A., & Mallet, C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.006 · Cited by 32
Self-citationMetabolism of AM404 From Acetaminophen at Human Therapeutic Dosages in the Rat Brain
Muramatsu, S., Shiraishi, S., Miyano, K., Sudo, Y., Toda, A., Mogi, M., Hara, M., Yokoyama, A., Kawasaki, Y., Taniguchi, M., et al. (2016) · Anesthesiology and Pain Medicine · doi:10.5812/aapm.32873 · Cited by 32 · cited 6×
“Theoretically, combining two analgesics with different mechanisms of action potentiates their analgesic actions without increasing their doses and compromising the safety outcomes.103–106 Paracetamol has linear and consistent pharmacokinetics, and its tolerable profile makes it a good option when a combination is requ…”
BackgroundResultInfluentialCardiorenal Safety of OTC Analgesics
White, W. B., Kloner, R. A., Angiolillo, D. J., & Davidson, M. H. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417751070 · Cited by 31
Acetaminophen use and change in blood pressure in a hypertensive population
Dawson, J., Fulton, R., McInnes, G. T., Morton, R., Morrison, D., Padmanabhan, S., Hewitt, J., Meredith, P., Muir, S., Dominiczak, A. F., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328360f6f8 · Cited by 27
What dose of paracetamol for older people?
(2018) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2018.6.0636 · Cited by 27
Qi, D. S., May, L. G., Zimmerman, B., Peng, P., Atillasoy, E., Brown, J. D., & Cooper, S. A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.11.003 · Cited by 26 · cited 1×
“This was in line with another clinical trial showing similar rates of treatment-related adverse events between the higher and lower single doses of paracetamol.(85) Still, the safety of paracetamol is surrounded by controversy.”
ResultDavison, S. N., Rathwell, S., George, C., Hussain, S. T., Grundy, K., & Dennett, L. (2020) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358120910329 · Cited by 25 · cited 1×
“Thus, paracetamol remains the mainstay analgesic option in patients with chronic kidney disease.(92) It is unnecessary to modify the dose for dialytic patients; however, dose reduction or longer dose interval should be considered in patients with advanced kidney failure.”
BackgroundThe need for fundamental reforms in the pain research field to develop innovative drugs
Nagakura, Y. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1261108 · Cited by 25 · cited 1×
“Introduction Pain represents substantial healthcare and financial burden despite the available pain management approaches, highlighting the urgent need for innovative medications and, possibly, indications of established analgesics.(1) Non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol (also known as aceta…”
BackgroundPickering, G., Creveaux, I., Macian, N., & Pereira, B. (2020) · Pain Medicine · doi:10.1093/pm/pnz037 · Cited by 23 · cited 1×
“As a confirmation of the role of TRPV1 in humans, Pickering et al demonstrated the involvement of a specific TRPV1 rs224534 variant in paracetamol antinociception in healthy volunteers.(51)”
BackgroundParacetamol–Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug
Sodano, F., Lazzarato, L., Rolando, B., Spyrakis, F., Caro, C. D., Magliocca, S., Marabello, D., Chegaev, K. Y., Gazzano, E., Riganti, C., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00508 · Cited by 22
Adamantyl Analogues of Paracetamol as Potent Analgesic Drugs via Inhibition of TRPA1
Fresno, N., Pérez-Fernández, R., Goicoechea, C., Alkorta, I., Fernández-Carvajal, A., de la Torre-Martínez, R., Quirce, S., Ferrer-Montiel, A., Martín, M. I., Goya, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113841 · Cited by 22 · cited 1×
“Adamantyl, a paracetamol analog that selectively inhibits the TRPA1 receptor, was also proposed.(129)”
BackgroundAweke, Z., Seyoum, F., Shitemaw, T., & Neme, D. (2020) · BMC Anesthesiology · doi:10.1186/s12871-020-01115-6 · Cited by 22
Singh, A. M., Kirsch, J. M., Patel, M. S., Gutman, M. J., Harper, T., Lazarus, M. D., Horneff, J. G., Namdari, S., Voskeridjian, A. C., & Abboud, J. A. (2021) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2021.03.132 · Cited by 22
Epitranscriptomic Reprogramming Is Required to Prevent Stress and Damage from Acetaminophen
Evke, S., Melendez, J. A., Lin, Q., & Begley, T. J. (2022) · Genes · doi:10.3390/genes13030421 · Cited by 21 · cited 1×
“Interestingly, a recent work studying the role of acetaminophen on epitranscriptome suggests that its hepatotoxicity could be reduced by adequate strategy.(86) Otherwise, although some other safety issues associated with paracetamol remain inconclusive, some patients with comorbidities have concerns with the use of pa…”
BackgroundAboul‐Fadl, T., & Omar, F. A. (1998) · Inflammopharmacology · doi:10.1007/s10787-998-0031-3 · Cited by 19
Development of acetaminophen proline prodrug
Wu, Z., Patel, A. D., Dave, R. H., & Yuan, X. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.05.050 · Cited by 19
Å.Nilsson, J. L., Mallet, C., Shionoya, K., Blomgren, A., Sundin, A. P., Grundemar, L., Boudieu, L., Blomqvist, A., Eschalier, A., Nilsson, U. J., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113042 · Cited by 17 · cited 1×
“It has been recently shown that paracetamol amine analogs undergo FAAH-dependent transformation into TRPV1 activators without producing hepatotoxicity at the same dose that paracetamol produces clinically relevant hepatotoxicity; these analogs exhibited dose-dependent antinociceptive effects without antipyretic action…”
BackgroundSelf-citationTropisetron and paracetamol association in post‐operative patients
Pickering, G. P., Faure, M., Commun, F., de Boissy, E. C., Roche, G., Mom, T., Simen, E., Dubray, C., Eschalier, A., & Gilain, L. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00933.x · Cited by 16
Self-citationAtkinson, H. C. (2015) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.1000230 · Cited by 16 · cited 1×
“Previous pharmacokinetic reports demonstrated the lack of significant interactions in the pharmacokinetic profiles of ibuprofen and paracetamol when administered in a fixed-dose combination tablet, highlighting that the effect of this combination is primarily a pharmacodynamic one.(117,118) Thus, the paracetamol/ibupr…”
BackgroundHamurtekin, Y., NOUILATI, A., DEMİRBATIR, C., & Hamurtekin, E. (2020) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2018.35403 · Cited by 16 · cited 1×
“As an example, the involvement of 5-HT3 receptors has been discussed in humans, and experimental work in rodents with 5-HT3 receptor antisense oligonucleotides showed that they were not involved in the analgesic effect of paracetamol, while a tropisetron-sensitive receptor was.(74) However, investigations showed that…”
BackgroundParacetamol: Update on its Analgesic Mechanism of Action
Mallet, C., Eschalier, A., & Daulhac, L. (2017) · Pain Relief - From Analgesics to Alternative Therapies · doi:10.5772/66649 · Cited by 11
Self-citationMititelu Tartau, L., Popa, E. G., Lupusoru, R. V., Lupusoru, C. E., Stoleriu, I., & Ochiuz, L. (2014) · Pharmacology · doi:10.1159/000362649 · Cited by 10
Liu, J., Di, J., Zhang, Y., & Xing, E. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00828-5 · Cited by 10
Yamaguchi, C., Yamamoto, D., Fujimaru, Y., Asano, T., & Takaoka, A. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00178 · Cited by 10
Gaul, C., & Eschalier, A. (2018) · The Open Pain Journal · doi:10.2174/1876386301811010012 · Cited by 8 · cited 1×
“Both direct and indirect comparisons demonstrated analgesic superiority of higher single dose compared to lower single doses, highlighting that a higher single dose of paracetamol for a short duration (4–5 days) poses more benefit than lower single doses.(80) This observation is consistent with the successful experime…”
ResultSelf-citationNakamura, S., Nonaka, T., Komatsu, S., Yamada, T., & Yamamoto, T. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112578 · Cited by 8 · cited 1×
“However, investigations showed that p-aminophenol analgesic action was mediated by the bulbospinal serotonergic system,(18) which may suggest an involvement of this serotonergic system in the AM404 antinociceptive activity, as recently suggested.(63) Finally, if bulbospinal serotoninergic pathways seem to be involved…”
BackgroundPharmacological screening of glycine amino acid prodrug of acetaminophen
Parashar, A. (2015) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.153431 · Cited by 6
Perrot, S., Eschalier, A., Desmeules, J., Lanteri-Minet, M., & Attal, N. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2076475 · Cited by 6
Self-citationThe rediscovery of paracetamol
Mallet, C., & Eschalier, A. (2018) · Oxford Medicine Online · doi:10.1093/med/9780198834359.003.0004 · Cited by 4
Self-citationThybo, K. H., Hägi‐Pedersen, D., Wetterslev, J., Dahl, J. B., Jakobsen, J. C., Pedersen, N. A., Jakobsen, K., Bülow, H. H., Ibsen, L., Overgaard, S., et al. (2020) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.13496 · Cited by 4 · cited 1×
“The benefit of the paracetamol/ibuprofen combination was not significantly influenced by age, sex, or type of anesthesia.(121) Notably, comparative trials also showed that the non-narcotic paracetamol/ibuprofen combination had a similar or higher analgesic effect compared to the acetaminophen/codeine approach.”
Result
Research works printed but not linked: 4
- Boutaud, 2002, Proc Natl Acad Sci U S A, 99, 7130, 10.1073/PNAS.102588199/ASSET/682AB754-3CF6-4EC9-B4FB-18483C903C21/ASSETS/GRAPHIC/PQ1025881008.JPEG · doi:10.1073/pnas.102588199/asset/682ab754-3cf6-4ec9-b4fb-18483c903c21/assets/graphic/pq1025881008.jpeg
- Jozwiak-Bebenista, 2014, Acta Pol Pharm Drug Res, 71, 11
- Evke, 2022, Genes, 13, 10.3390/GENES13030421/S1 · doi:10.3390/genes13030421/s1
- Schug, 2006, Clin Rheumatol, 25, 16, 10.1007/S10067-006-0202-9/FIGURES/5 · doi:10.1007/s10067-006-0202-9/figures/5
Cited by
Inflammation and cancer: friend or foe?
Smith, A. D. T., Córdoba-Hernandez, S., Mejía-Guarnizo, L. V., Monroy-Camacho, P. S., & Rodríguez-García, J. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1385479 · Cited by 58
Hallmarks of primary headache: part 2– Tension-type headache
Pan, L. H., Ling, Y., Wang, S., Al‐Hassany, L., Chen, W., Chiang, C., Cho, S., Chu, M. K., Coppola, G., Pietra, A. D., et al. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-02098-w · Cited by 61
“…effects primarily through the peripheral inhibition of the cyclooxygenase (COX-1 and COX-2) pathway, whereas paracetamol analgesic effects are more complex and involve inhibition of COX-2 and other central pathways, such as the endocannabinoid and serotonergic pathways (reviewed in [295, 296]).”
Pain Management in Children Admitted to the Emergency Room: A Narrative Review
Cunico, D., Rossi, A., Verdesca, M., Principi, N., & Esposito, S. (2023) · Pharmaceuticals · doi:10.3390/ph16081178 · Cited by 29
“This is formed in the central nervous system (CNS) from the liver metabolite of PC, p-aminophenol, under the action of the fatty acid amide hydrolase (FAAH) enzyme [63].”
BackgroundMolecular Mechanisms of Chronic Pain and Therapeutic Interventions
Li, Z., Li, X., Liu, J., Sun, R., Ye, Y., Xiang, H., Luo, F., Li, S., & Luo, A. (2025) · MedComm · doi:10.1002/mco2.70325 · Cited by 36
“2 channel, thereby reinforcing the activity of descending serotonergic pathways [316] CPPP, OA, headache, migraine attacks [316–318] Tricyclic antidepressants (TCAs) Hindering the reuptake process of serotonin and noradrenaline [2, 319]; modulation of opioid, glutamatergic and endocannabinoid…”
Jasim, M. H. M., & Mustafa, Y. F. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401309 · Cited by 20
Metadata
- Authors
- Mallet, C., Desmeules, J., Pegahi, R., & Eschalier, A.
- Affiliations
- Inserm (FR)
- University of Geneva (CH)
- Corresponding author
- Eschalier, Alain
- Venue
- Journal of Pain Research
- Publisher
- Informa UK Limited
- Published
- 2023-03
- Volume
- Volume 16
- Pages
- 1081-1094
- ISSN
- 1178-7090 (ISSN-L)
- PMC
- PMC10066900
- OpenAlex
- W4361217917
- Cited by
- 83
- References
- 137
- Citations by year
- 2026: 22 · 2025: 33 · 2024: 17 · 2023: 11
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Pain Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Keywords
- paracetamol, analgesic mechanism, TRPV1, periaqueductal gray, mGlu5 receptor, central analgesia, acute pain, NSAID combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.